FRIDAY, Jan. 11, 2019 (HealthDay News) — Deadly lung attacks may be averted in some COPD patients with a daily dose of vitamin D, new research suggests. Chronic obstructive pulmonary disease, or COPD, includes a number of lung conditions, including emphysema and chronic bronchitis. Nearly all COPD deaths are due to a sudden worsening of… Read More »
December 31, 2018 Share this content: There are 2 hypotheses on why high-intensity NIV is beneficial to individuals with hypercapnic stable COPD. There is evidence that people with comorbid stable chronic obstructive pulmonary disease (COPD) and chronic hypercapnic respiratory failure (CHRF) have improved symptoms and survival rates with high-intensity noninvasive ventilation (NIV), according to a… Read More »
December 18, 2018 Share this content: Higher initial costs associated with CBT were offset by savings resulting from fewer hospital admissions and emergency department visits in the subsequent 12 months. Cognitive behavioral therapy (CBT) interventions were statistically and clinically superior to self-help leaflets in the treatment of anxiety in patients with chronic obstructive pulmonary disease… Read More »
November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »
FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD) Print this page DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ: MYL) (“Mylan”) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for… Read More »